[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554481":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":44,"collaborators":26,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":26,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":26,"enrollmentInfo":55,"targetDuration":26,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":69,"whyStopped":26,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"IBSA Farmaceutici Italia Srl","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","PLACEBO_COMPARATOR","Patients under H. pylori eradication therapy and placebo as treatment",[13],"Dietary Supplement: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Treated group","EXPERIMENTAL","Patients under H. pylori eradication therapy and probiotics as treatment",[19],"Dietary Supplement: IBSA Probiotics",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","IBSA Probiotics","Dietary supplement base on probiotic strains.",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","The placebo does not contain functional components, and the appearance is indistinguishable from the comparison product.",[9],[32],{"facility":33,"status":26,"city":34,"state":35,"zip":36,"country":35,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":26},"Policlinico S. Orsola - Malpighi - Università di Bologna","Bologna","Italy","40138","IT",{"type":39,"coordinates":40},"Point",[41,42],11.33875,44.49381,{"lat":42,"lon":41},{"type":45,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100554481","assessment-of-the-adjuvant-role-of-dietary-supplementation-of-antibiotic-tolerant-probiotics-in-standard-therapy-for-the-eradication-of-helicobacter-pylori-infection-100554481",false,"NCT06499649","Assessment of the Adjuvant Role of Dietary Supplementation of Antibiotic-tolerant Probiotics in Standard Therapy for the Eradication of Helicobacter Pylori Infection.","Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Adjuvant Role of Dietary Supplementation of Antibiotic-tolerant Probiotics in Standard Therapy for the Eradication of Helicobacter Pylori Infection.","Inclusion Criteria:\n\n* Diagnosis of H. pylori infection by breath test and histological and\u002For cultural examination on biopsy (performed within 10 days prior to T0)\n* Prescription of eradication therapy for HP\n* Naïve patients (who have never had eradication therapy for H. pylori)\n* Patients with symptoms of upper gastrointestinal tract\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* Patients with history of previous eradication attempts\n* Patients with known gastric disease (e.g. atrophic gastritis, gastric cancer)\n* Patients with severe organ dysfunction (cirrhosis of the liver, severe renal or respiratory failure, dialysis)\n* Women who are pregnant or breastfeeding\n* Patients unable to provide informed consent","ALL","18 Years",{"count":56,"type":57},270,"ACTUAL","INTERVENTIONAL",[60],"NA","Randomized, double-blind, placebo-controlled clinical study to assess the adjuvant role of dietary supplementation of antibiotic-tolerant probiotics, derived from Lactobacillus acidophilus and Bifidobacterium animalis, in standard therapy for the eradication of Helicobacter pylori infection.",[63],"Helicobacter Pylori Infection",[65,66,67,68],"Probiotics","Dietary Supplementation","Eradication Therapy","Double-blinded","COMPLETED","2025-07-07",{"date":72,"type":57},"2025-07-08",{"date":74,"type":57},"2024-07-03",{"date":76,"type":57},"2025-05-05",{"name":5,"class":6},1]